Hedge the rise in your health insurance premium with these 2 ASX stocks

Sick of price rises? Get on the other side of the transaction.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Health insurance premiums are set to rise by an average of 3.73% on 1 April. While this can be a bitter pill to swallow for consumers, it can be a good opportunity for investors.

To hedge the price hike, ASX investors could consider adding companies that stand to benefit to their portfolios.

Three health professionals at a hospital smile for the camera.

Image source: Getty Images

Changes go into effect on 1 April

After several rounds of negotiations between Health Minister Mark Butler and insurance companies, health insurance premiums will rise by an average of 3.73% in April. 

Each year, the health minister must approve the annual premium rises of private health insurance. This directly impacts more than half of Australia's population, with an estimated 13.6 million Australians having private health insurance, according to The Department of Health and Aged Care

This marks an acceleration from last year, when health premiums rose by an average of 3.03%. It also represents the largest increase in seven years. 

Instead of simply absorbing the rise in premiums, investors can benefit from the price hike by investing in the companies themselves. 

Some healthcare funds, such as the two listed below, have above-average price rises.

Medibank Private Ltd (ASX: MPL)

Medibank Private is Australia's largest private health insurance provider. Covering more than 4.2 million customers in 2024, Medibank directly benefits from higher health insurance premiums. Next month, Medibank will increase its premium by 3.99%. 

Medibank has proven a fruitful investment over the past five years, with its share price increasing more than 65%. Medibank also offers a dividend yield of 3.89%.

NIB Holdings Ltd (ASX: NHF)

Another health insurance company that is increasing its premiums above the average is NIB. It provides health and medical insurance to more than 1.5 million Australian and New Zealand residents. Next month, it will increase premiums by 5.79%, significantly above the average.

While not quite as attractive as Medibank Private, NIB has increased more than 30% over the past five years and offers a dividend yield of 4.02%.

Foolish takeaway

With rising inflation, price hikes have been a common theme over the past few years. In this case, those impacted by health insurance price rises can hedge their expenses by getting on the other side of the transaction and investing in the health insurance companies themselves. Funds with higher increases than the average may be especially compelling.

If the next five years are anything like the last five years, investing in Medibank Private and NIB could be a wise move.

Motley Fool contributor Laura Stewart has no positions in any of the stocks mentioned.The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »